MiNK Therapeutics, Inc. 8-K

What Happened

• MiNK Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026 and furnished a press release dated May 15, 2026 as Exhibit 99.1 to its Form 8-K (filed May 15, 2026).
• The Form 8-K reports Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Exhibits). The report is signed by CEO Jennifer S. Buell.

Key Details

• Event date: May 15, 2026 (press release and 8-K filing).
• Reporting period: quarter ended March 31, 2026.
• Exhibit furnished: 99.1 — Press Release dated May 15, 2026 announcing the quarterly results.
• Form signed by: Jennifer S. Buell, Chief Executive Officer.

Why It Matters

• Quarterly results and the accompanying press release are the company’s primary update on recent earnings, revenue, cash position and operating results—information investors use to assess near-term performance.
• This Form 8-K furnishes the press release but does not itself present detailed financial statements; investors should review the Exhibit 99.1 press release and subsequent SEC filings (e.g., 10-Q) for the full financial metrics and management commentary.